Patients with chronic spontaneous urticaria experienced substantial reductions in hives and itch with briquilimab through 16 weeks of treatment, with responses as early as week 1, according to an ...

An allergic reaction in babies can range from mild to life-threatening. Here’s how to tell if your child is having an ...

Omalizumab biosimilar is under clinical development by Mabpharm and currently in Phase III for Chronic Urticaria Or Hives.

Kwatra: Chronic spontaneous urticaria — that's a mouthful ... practitioner when even talking about this disease, let alone treatment options? Kwatra: The number-one thing the patients want ...

As the company approaches critical data readouts, investors and analysts are closely watching its progress in the competitive landscape of chronic urticaria treatments. InvestingPro analysis ...

By Stephen Beech A new way of treating common inflammatory skin conditions such as eczema is on the horizon, according to a ...

Analyst Silvan Tuerkcan of JMP Securities reiterated a Buy rating on Allakos (ALLK – Research Report), with a price target of $3.00.Stay Ahead ...

As the company approaches critical data readouts, investors and analysts are closely watching its progress in the competitive landscape of chronic urticaria treatments. InvestingPro analysis reveals ...

Rapid onset of deep and durable clinical responses observed across multiple dosing cohorts with a favorable safety profile ...

Analyst Etzer Darout from BMO Capital reiterated a Buy rating on Jasper Therapeutics (JSPR – Research Report) and keeping the price target at ...